ClinicalTrials.gg
RecruitingNCT06792994CLL2000Updated Apr 30, 2026

A Prospective Observational Trial to Assess Treatment Sequences and Factors That Impact Overall Sur-vival in Patients With Chronic Lymphocytic Leukaemia (CLL) Treated Within First-line Studies of the GCLLSG

An observational study in Chronic Lymphocytic Leukemia, sponsored by German CLL Study Group. Recruiting at 2 sites in Germany. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-04-30.

Sponsored by German CLL Study Group · Observational

How we know

From the registry’s dates

  • Started Apr 2026; still recruiting 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
2,000
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 25 studies in Leukemia, Lymphocytic, Chronic, B-Cell by German CLL Study Group — 2 open to participants now, 2 under way, 1 of them phase 3. Leukemia, Lymphocytic, Chronic, B-Cell · German CLL Study Group.

Started
2026
the only one that year
Observational
Only one
of the 25
Registered
25th of 25
by date

Among the 25 studies in Leukemia, Lymphocytic, Chronic, B-Cell by German CLL Study Group, this one is the only one that started in 2026, is the only observational one, and was the 25th registered.

Leukemia, Lymphocytic, Chronic, B-Cell

2,039 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 237 are open to participants now.

Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →

Open to participants now

2 of the 25 studies in Leukemia, Lymphocytic, Chronic, B-Cell by German CLL Study Group are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 187 Leukemia, Lymphocytic, Chronic, B-Cell studies recruiting now, 151 (81%) set no upper age limit and 15 (8%) stop at 75 or younger; 18 take children under 18; 12 take healthy volunteers.

This study: 18 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies in Leukemia, Lymphocytic, Chronic, B-Cell by German CLL Study Group, or all of them as a file.
02

Study summary

This observational trial is designed to investigate long-term survival with regard to the primary endpoint overall survival (OS) after start of first-line treatment.

Read the detailed description

Primary objective:

To assess the overall survival (OS) from initiation of first-line treatment in patients who received different first-line therapies within the CLL13, CLL14, or CLL17 clinical trials.

Rationale for primary objective:

CLL is the most common leukaemia in adults in the western countries with an age-standardized incidence between 4 and 5 cases per 100,000 person-years and about 5,500 new CLL cases in Germany1. The clinical course of CLL is highly variable and can be predicted by clinical staging (according to Rai and Binet2,3) as well as genetic4, serum and other markers. Due to the increasing effectiveness of approved first-line therapies, some patients with CLL experience a normal life expectancy. Therefore, the total duration of clinical trials would need to be enormously extended in order to capture data on OS which is operationally not practicable. Moreover, a number of effective treatment options are available for follow-up therapies. Hence, the analysis of OS might not only be affected by the choice of first-line therapy but also by subsequent therapies and other competing factors that should be collected. Studies on long-term survival of patients with CLL have primarily relied on registry data5 and population-based studies6 and were conducted outside of clinical trials. These studies only occasionally consider specific comorbidities7,8, are retrospective in nature9, and often have limited observation periods. In addition, a potential accrual bias may be difficult to address within the format of registry data collection.

Prospective follow-up of patients would enable more comprehensive analyses within a predefined study patient population. This observational trial aims to prospectively analyze OS for a predefined study population. Patients who received first-line treatment in CLL1310, CLL1411, or CLL17 trials conducted by the German CLL Study group (GCLLSG) will be included to carry out this comprehensive analysis of OS in a well-defined patient population. To capture OS, all data that could influence OS, including but not limited to the presence of genomic risk factors and concomitant conditions at different time points, age, sex, country, subsequent lines of therapy and the occurrence of other diseases including causes of death, will also be recorded. In addition, data that had been collected within the initial first-line studies will be included in the analyses.

Secondary objectives:

To assess efficacy, measured by different time-to-event parameters from second-line treatment, and additionally from first-line treatment, particularly for those patients who have not yet received subsequent treatment lines.

Quality of life and safety (types, frequencies and follow-up adjusted incidence rates of second primary malignancies [SPM] and Richter's transformations [RT] as well as causes of death) will be assessed.

Rationale for secondary objectives:

OS and quality of life are considered the two most important endpoints in clinical research (Leary A. et al. Viewpoint Lancet 2024 ). Hence, with prolonged survival times and competing causes of death it is rather difficult to adequately capture these endpoints.

Patients with CLL have a significantly higher risk of developing SPMs compared to the general population12-16. The underlying mechanisms for this increased risk are not fully understood, but likely involve a combination of factors including tumor microenvironment, immunosuppression17, genetic predisposition, previous treatment15,18, aging and environmental exposures19. These SPMs can include various types of skin cancers such as non-melanoma skin cancer and malignant melanoma, as well as solid tumors (e.g., lung, breast, colon) and other hematologic malignancies (e.g., acute myeloid leukemia, non-Hodgkin lymphoma). With improved efficacy of treatment options with targeted agents, there is growing recognition, that the increased risk of SPMs may influence the OS of patients with CLL. The collection of long-term data based on the choice of first-line treatment in CLL patients and numbers, type and duration of subsequent therapies is essential not only for the analysis of OS, but equally for understanding the frequency of RT/SPMs. Such data will support informed treatment decision-making, risk stratification, and personalized medicine approaches, ultimately improving patient outcomes and guiding the development of safer and more effective CLL therapies. Therefore, investments in longitudinal data collection and collaborative research initiatives focusing on this important aspect of CLL management are warranted to optimize patient care and advance our understanding of CLL treatment-related complications.

In addition, progression-free survival (PFS) and time-to-next CLL treatment (TTNT) in patients who underwent their initial therapy within the CLL1320, CLL1411 or CLL17 trial will be analysed from first-line treatment, and OS, PFS and TTNT will also be analysed from second-line treatment.

Exploratory objectives:

Blood samples from all patients will be collected within routine clinical surveillance no more than once a year, to allow for exploratory analyses such as measurable residual disease (MRD) and other biomarkers.

Rationale for exploratory objectives:

The collection of blood samples, though seemingly interventional, can be scientifically justified since the collection aligns with routine clinical practice (during follow up in clinical routine, blood samples are required for each follow-up visit to assess the status of the disease). Because blood sampling is part of each routine visit, the blood samples drawn and collected for this study pose minimal physical and psychological risk to participants. Without the introduction of therapeutic or diagnostic interventions, analysis of blood samples may enable the identification of biomarkers that can help understand disease mechanisms, predict outcomes, or identify patient subgroups. The integration of blood sample data into an observational study bridges the gap between clinical observations and basic research. This can uncover molecular insights that drive innovation without altering the study's observational nature.

To maintain the integrity of the observational design, study participants will be fully informed about the purpose, use, and risks of blood sample collection. It will be explained in the patient informed consent form, that the consent to blood sampling is optional. No additional visit and no additional venal puncture will be required. By ensuring ethical and practical considerations, the study will maintain its observational nature while enabling valuable translational and clinical insights.

03

Conditions studied

  • Chronic Lymphocytic Leukemia

Keywords

  • Long-term observation, CLL
04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

This observational trial will enrol patients who received first-line treatment in either CLL13, CLL14, or CLL17 trial. On ground of feasibility the sample size is estimat-ed at 1800-2000 patients in total. No formal sample size calculation has been performed.. The study population is defined as all patients who received first-line treatment in CLL13, CLL14, or CLL17 trial, regardless of whether they received any subse-quent lines of CLL therapy or not.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

    • Subjects must voluntarily sign and date an , ap-proved by an independent ethics committee (IEC)/institutional review board (IRB)

      • Documented diagnosis of CLL at time point of inclusion in a study of the GCLLSG (development of RT is not an exclusion criterion)
      • First-line treatment was administered within one of these first-line studies of the GCLLSG (CLL13, CLL14, or CLL17).
      • Subsequent therapy lines were either documented during the participa-tion in a first-line study of the GCLLSG or patient consented to have the subsequent therapy lines documented within this observational trial.
      • Subjects are willing and able to comply with procedures required in this protocol.

Exclusion criteria

Exclusion Criteria:

    • Patients without participation in one of the studies of the GCLLSG (CLL13, CLL14, CLL17)

      • Subjects with legal incapacity
      • Subjects who are institutionalized by regulatory or court order
      • Subjects who are in dependence to the sponsor or the investigator
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
2,000 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Patienst with CLL who received at least firstline treatment within a clinical trial

    This trial will enroll patients who received first-line treatment in either CLL13, CLL14, or CLL17 trial. On ground of feasibility the sample size of the study is estimated at approximately 1800-2100 patients in total. No formal sample size calculation has been performed

    Other: Observational

Interventions

  • OtherObservational

    The data of this observational trial will be collected as part of routine patient care. Data relating to the time period between the end of participation in the clini-cal first-line trial (CLL13, CLL14, or CLL17) and inclusion in the observational trial will be documented retrospectively at the time point of inclusion in the observa-tional trial. From inclusion in the observational trial, data on survival, long-term efficacy, quality of life, and safety will be collected prospectively

06

What researchers measure

Primary outcomes

  1. Overall Survival

    This observational trial is designed to investigate long-term survival with regard to the primary endpoint overall survival (OS) after start of first-line treatment.

    Time frame: Each patient will be followed until death or end of study, whatever occurs first, i.e. 60 months from start nof enrolment.

07

Study locations

2 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Aug 2030, 51 months after the start.

Of 70 non-industry observational studies under Leukemia, Lymphocytic, Chronic, B-Cell, half reached primary completion within 62 months of starting (the median), counting those still running; a quarter within 30. This study's planned 51 months is below that.

Counting every sponsor, half of 104 studies reached it within 60 months; a quarter within 31 and three quarters within 176.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 20, 2025
First posted
Jan 27, 2025
StartActual
Apr 2, 2026
Primary completionEst.
Aug 1, 2030
CompletionEst.
Aug 1, 2030
Last update
Apr 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06792994
Lead sponsor
German CLL Study Group
Collaborators
GELLC (Grupo Español de Leucemia Linfocítica Crónica), Nordic Lymphoma Group, Polish Adult Leukemia Group, HOVON - Dutch Haemato-Oncology Association
Responsible party
Sponsor
First posted
Jan 27, 2025
Start date
Apr 2, 2026
Primary completion
Aug 1, 2030 (estimated)
Completion
Aug 1, 2030 (estimated)
Last update
Apr 30, 2026

Study contacts

Kirsten Fischer, MD
Contact
kirsten.fischer@uk-koeln.de
+4922147888220 ext. +4922147888220
Aline Zey, Dipl.Biol.
Contact
aline.zey@uk-koeln.de
+4922147888220 ext. +4922147888220
BArbara F. Eichhorst, MD
study chair · Uniklinik Köln

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion